• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Protein J . Evolution of Stronger SARS-CoV-2 Variants as Revealed Through the Lens of Molecular Dynamics Simulations

tetano

Editor, Senior Moderator
Protein J


. 2022 Aug 1.
doi: 10.1007/s10930-022-10065-6. Online ahead of print.
Evolution of Stronger SARS-CoV-2 Variants as Revealed Through the Lens of Molecular Dynamics Simulations


Alec J Wozney[SUP] 1 [/SUP], Macey A Smith[SUP] 1 [/SUP], Mobeen Abdrabbo[SUP] 1 [/SUP], Cole M Birch[SUP] 1 [/SUP], Kelsey A Cicigoi[SUP] 1 [/SUP], Connor C Dolan[SUP] 1 [/SUP], Audrey E L Gerzema[SUP] 1 [/SUP], Abby Hansen[SUP] 1 [/SUP], Ethan J Henseler[SUP] 1 [/SUP], Ben LaBerge[SUP] 1 [/SUP], Caterra M Leavens[SUP] 1 [/SUP], Christine N Le[SUP] 1 [/SUP], Allison C Lindquist[SUP] 1 [/SUP], Rikaela K Ludwig[SUP] 1 [/SUP], Maggie G O'Reilly[SUP] 1 [/SUP], Jacob H Reynolds[SUP] 1 [/SUP], Brandon A Sherman[SUP] 1 [/SUP], Hunter W Sillman[SUP] 1 [/SUP], Michael A Smith[SUP] 1 [/SUP], Marissa J Snortheim[SUP] 1 [/SUP], Levi M Svaren[SUP] 1 [/SUP], Emily C Vanderpas[SUP] 1 [/SUP], Aidan Voon[SUP] 1 [/SUP], Miles J Wackett[SUP] 1 [/SUP], Moriah M Weiss[SUP] 1 [/SUP], Sanchita Hati[SUP] 2 [/SUP], Sudeep Bhattacharyya[SUP] 3 [/SUP]



Affiliations

Abstract

Using molecular dynamics simulations, the protein-protein interactions of the receptor-binding domain of the wild-type and seven variants of the severe acute respiratory syndrome coronavirus 2 spike protein and the peptidase domain of human angiotensin-converting enzyme 2 were investigated. These variants are alpha, beta, gamma, delta, eta, kappa, and omicron. Using 100 ns simulation data, the residue interaction networks at the protein-protein interface were identified. Also, the impact of mutations on essential protein dynamics, backbone flexibility, and interaction energy of the simulated protein-protein complexes were studied. The protein-protein interface for the wild-type, delta, and omicron variants contained several stronger interactions, while the alpha, beta, gamma, eta, and kappa variants exhibited an opposite scenario as evident from the analysis of the inter-residue interaction distances and pair-wise interaction energies. The study reveals that two distinct residue networks at the central and right contact regions forge stronger binding affinity between the protein partners. The study provides a molecular-level insight into how enhanced transmissibility and infectivity by delta and omicron variants are most likely tied to a handful of interacting residues at the binding interface, which could potentially be utilized for future antibody constructs and structure-based antiviral drug design.

Keywords: COVID-19; Delta; Molecular dynamics; Omicron; SARS-CoV-2; Spike protein.
 
Back
Top Bottom